TheranosticTrials.org

Clinical Trial · NCT04436406

PD-L1 Expression in Cancer (PECan Study).

Overview

Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study. To determine the baseline level and variability within and between patients and tumour types of PD-L1 expression in melanoma and non-small cell lung cancer in immunotherapy naïve patients using \[99mTc\]-anti-PD-L1 SPECT/CT and immunohistochemistry.

Sponsor

The Christie NHS Foundation Trust

Phase

N/A

Contacts

Daniel J Hughes, MBBS MRCP (CONTACT)

daniel.hughes@kcl.ac.uk

020 7188 7188

Gary JR Cook (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04436406

Drug / Compound

NM-01

Isotope(s):
Target(s):
  • PD-L1
Ligand Class: Small Proteins and Antibody Fragments

Eligibility

Inclusion

  • Willingness and ability to comply with scheduled study visits and tests.
  • Patients with histologically confirmed NSCLC or melanoma scheduled for PD1/PDL1 immunotherapy alone or in combination with other systemic anti-cancer therapy.

Exclusion

  • Patients who have received other systemic anti-cancer therapy within preceding 14 days
  • More than 3 months between IHC PDL1 and study recruitment
  • Patients likely to require palliative radiotherapy within the first 12 weeks of treatment or radiotherapy to target lesion(s) received within preceding 42 days
  • Previous anticancer treatment with any checkpoint inhibitor or other immunotherapy, i.e. only immunotherapy naïve patients